Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.
| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Merus N.V. | Zenocutuzumab (Zeno) in combination with Trastuzumab and Vinorelbine | Metastatic breast cancer | Phase 2 | Data Released | Intravenous | Oncology |
| Merus N.V. | Petosemtamab (MCLA-158) | Recurrent/metastatic (r/m) head and neck squamous cell carcinoma (HNSCC), Solid Tumors | Phase 2 | Data Released | Intravenous | Oncology |
| Mesoblast Limited | Revascor (Rexlemestrocel-L) - (DREAM-HF) | Heart failure | BLA Filing | Type Meeting | Intracoronary | Cardiology |
| Mesoblast Limited | Ryoncil (remestemcel-L) - (BMT CTN trial) | Steroid-refractory acute graft versus host disease (SR-aGvHD) | Phase 3 | Enrollment Initiation | Intravenous | Immunosuppressant |
| Mesoblast Limited | MPC-150-IM | End-Stage Heart Failure with LVADs | Phase 2b | Trial Completed | Intramuscular | Cardiology |
| Mesoblast Limited | MPC-300-IV | Rheumatoid arthritis | Phase 2 | Trial Discontinued | Intravenous | Immunology: Anti-TNF |
| MetaVia Inc. | NB-01 | Diabetic neuropathic pain (DNP) | Phase 3 | Trial Discontinued | Oral | Neurology |
| MetaVia Inc. | ANA001 | COVID-19 | Phase 2/3 | Trial Planned | oral | COVID-19 |
